SUBSCRIBE
SUBSCRIBE

BioSpace Insights

The BioSpace Insights team performs research and analysis on industry trends for BioSpace and clients, producing industry reports, podcasts, events and articles.

Insights
Funding the Future of European Biotech
In this episode of Denatured, you’ll be hearing from Edoardo Negroni, co-founder & managing partner at AurorA-TT and Naveed Siddiqi, senior partner, Venture Investments at Novo Holdings. We debate whether Europe’s world-class science can be matched by a truly integrated venture ecosystem—and what it would take, in practice, to get there.
April 16, 2026
 · 
1 min read
 · 
Jennifer C. Smith-Parker
A conceptual story about finance in the Eurozone, featuring €10, €20, and €50 notes in a supermarket shopping cart, with €100 notes in the background.
Insights
Can Europe turn world-class science into world-class scale?
Despite exceptional regional hubs and research strength, investors say Europe still needs more integrated incubators, smarter regulation and broader pools of patient capital to keep breakthrough companies growing at home.
April 16, 2026
 · 
5 min read
 · 
Jennifer C. Smith-Parker
Drug Development
Whitepaper: CDMOs at a Crossroads
In this whitepaper, BioSpace reviews the major trends impacting the CDMO sector and the evolving relationship between sponsors and providers. We examine the key qualities pharma and biotech should consider in CDMO selection, and how the macroeconomic and macrodevelopment factors affecting the space play a role in this selection.
April 15, 2026
 · 
1 min read
 · 
BioSpace Insights
Job Trends
Report: Biopharma Job Market Report Q1 2026
BioSpace’s Biopharma Job Market Report reveals early signs of recovery for 2026. A rise in job postings, a surge in contract roles and strong M&A and IPO activity point to future hiring growth and shifts in hiring strategy.
April 9, 2026
 · 
1 min read
 · 
BioSpace Insights
Insights
Automation, Collaboration and the Future of Advanced Therapies
In this episode of Denatured, you’ll hear from Jason Jones, head of global business development at Cellular Origins and Alexander Seyf, founder & CEO of Autolomous. They discuss how the push to scale cell and gene therapy manufacturing is accelerating interest in automation, digitization, robotics and deeper collaboration across the ecosystem.
April 9, 2026
 · 
1 min read
 · 
Jennifer C. Smith-Parker
Prompt Engineering in AI Chatbot llm Application, Robotic Assistant with laptop dashboard chat message and Big data concept illustration
Insights
As CGT Manufacturing Scales Up, Automation and Collaboration Become Essential
As cell and gene therapy developers face rising pressure to produce therapies faster and at lower cost, the industry is leaning on robotics, digital systems and partnerships to bridge the gap between innovation and delivery.
April 8, 2026
 · 
3 min read
 · 
Jennifer C. Smith-Parker
IN PARTNERSHIP WITH API
Lean Derisking: Smart Ways to Cross Drug Development’s “Valley of Death”
Nobel laureate Sir Michael Houghton and colleagues at Applied Pharmaceutical Innovation (API) outline how rigorous early testing, smart IP and regulatory planning, and scalable CMC choices can help founders reach first-in-human faster.
April 6, 2026
 · 
4 min read
 · 
Jennifer C. Smith-Parker
Insights
The Radiotherapeutics Moment: How Isotopes are Changing Cancer Treatment
In this episode of Denatured, you’ll listen to Dr. Marc Hedrick, President and CEO of Plus Therapeutics and Dr. Phil Kantoff, CEO & Co-founder of Convergent Therapeutics. They discuss breakthroughs like alpha-emitting isotopes, supply chain solutions and why radiotherapeutics is biotech’s next big frontier.
April 2, 2026
 · 
1 min read
 · 
Jennifer C. Smith-Parker
3D rendering of a Syringe Shield and multiple instances of the international radioactive hazard symbol or the trefoil icon.
Insights
The Brave New World of Radiotherapeutics
Convergent Therapeutics’ Dr. Philip Kantoff and Plus Therapeutics’ Dr. Marc Hedrick discuss how unmet medical needs, maturing isotope supply chains and innovative delivery are positioning targeted radiation as oncology’s next big platform.
April 1, 2026
 · 
4 min read
 · 
Jennifer C. Smith-Parker
Insights
Beyond Buzzwords in Longevity Investing
In this episode of Denatured, you’ll listen to Sergey Jakimov, managing partner at LongeVC and Artem Trotsyuk, operating partner, US, LongeVC. We speak about how developers in the longevity space should stop chasing aging as an abstract target and concentrate on specific mechanisms that can clearly tackle age-related conditions.
March 26, 2026
 · 
1 min read
 · 
Jennifer C. Smith-Parker
Hourglass lying on pink background - Concept of time and woman
Insights
Validated Mechanisms, Strong Data Beat Hype in Longevity Investing
Longevity is a long-standing buzzword in life sciences, but it now has staying power. The smart trajectory is to stop chasing aging as an abstract target and concentrate on specific mechanisms that can clearly target specific, age-related diseases, according to two investors in a discussion with BioSpace.
March 23, 2026
 · 
3 min read
 · 
Jennifer C. Smith-Parker
Insights
Inside the Race to Build the Next Generation of AI Drug Discovery Platforms
In this episode of Denatured, you’ll listen to Viswa Colluru, CEO and founder of Enveda and Akshay Rai, principal, Healthcare & Biotech Investments at Premji Invest. We speak about how AI platforms must now prove themselves through proprietary data, focused pipelines and clinical readouts in competitive diseases to garner investor interest.
March 19, 2026
 · 
1 min read
 · 
Jennifer C. Smith-Parker
Job Trends
Report: 2026 U.S. Life Sciences Salary Report
BioSpace‘s 2026 U.S. Life Sciences Salary Report delivers a comprehensive look at how salaries, bonuses and benefits evolved over the past year amid ongoing economic pressure and workforce recalibration. It uncovers not just what people are earning, but how they’re thinking about compensation, career moves and total rewards in 2026.
March 19, 2026
 · 
1 min read
 · 
BioSpace Insights
IN PARTNERSHIP WITH PATSNAP
Webinar: The Agentic Test: Can AI Actually Accelerate Drug Development and Break Down Silos Across Pharma?
Every biopharma R&D and investment decision could be guided by connected intelligence. Join us to hear firsthand how agentic workflows and enterprise-scale data are helping drug developers move faster from molecule to market with greater confidence.
March 18, 2026
 · 
1 min read
 · 
BioSpace Insights
IN PARTNERSHIP WITH DIA
Webinar: Operationalizing AI in Drug Development: Inside DIA’s Global AI Consortium
This webinar introduces the DIA Artificial Intelligence Consortium, a neutral, public‑private partnership that convenes regulators, biopharmaceutical companies, academia, and technology providers, including FDA, Health Canada, MHRA, PMDA, IQVIA, Gilead, Otsuka, BeOne Medicines, Beth Israel Deaconess Medical Center–Yale School of Medicine, and others.
March 17, 2026
 · 
1 min read
 · 
BioSpace Insights
Load More